Invisible Ingredients: What Science Does—and Does Not—Know About Engineered Nanoparticles in Consumer Products

Pick up a tube of mineral sunscreen, a package of food wrapped in antimicrobial film, or a pair of odor-resistant athletic socks, and you are almost certainly holding a product that contains engineered nanoparticles. These materials—manufactured to operate at scales between one and one hundred nanometers—are embedded in an expanding catalog of consumer goods because of the remarkable functional properties they confer at that size range. Zinc oxide nanoparticles scatter ultraviolet radiation. Silver nanoparticles inhibit bacterial growth. Titanium dioxide nanoparticles whiten and preserve.

What the label will not tell you is how those particles behave once they enter the human body, accumulate in tissue over years of repeated exposure, or interact with biological systems in ways that differ fundamentally from their bulk material counterparts. The science on those questions is real, growing, and—by the candid admission of the researchers conducting it—still substantially incomplete.

Why Nanoparticles Behave Differently Than Their Bulk Equivalents

Understanding the concern requires grasping a core principle of nanoscale materials science: properties change dramatically as particle size decreases. A piece of bulk silver is chemically inert under most conditions. Silver nanoparticles, by contrast, exhibit potent antimicrobial activity precisely because their enormous surface-area-to-volume ratio accelerates ion release and enables interactions with cellular membranes that bulk silver cannot accomplish.

That same surface reactivity that makes silver nanoparticles effective against bacteria also makes them capable of interacting with human cells in ways that toxicologists are still characterizing. Particles at the nanoscale can cross biological barriers—including the blood-brain barrier and the gastrointestinal epithelium—that larger particles cannot. They can be internalized by cells through endocytosis, accumulate in organs, and trigger inflammatory responses through mechanisms that standard toxicological testing protocols were not designed to detect.

"We spent decades developing safety testing frameworks based on the chemistry of bulk materials," said a toxicologist at a major US research university who studies nanoparticle-cell interactions. "When you shrink a material to the nanoscale, you do not just get a smaller version of the same thing. You get a qualitatively different material with different biological behavior. Our testing frameworks have not fully caught up to that reality."

What the Current Science Shows

The peer-reviewed literature on nanoparticle toxicology is extensive but uneven. Some categories of engineered nanoparticles have been studied far more thoroughly than others, and findings across studies are often difficult to compare because researchers use different particle sizes, surface coatings, exposure concentrations, and biological models.

For titanium dioxide nanoparticles—used in sunscreens, food colorings, and paints—the International Agency for Research on Cancer classified the material as a possible human carcinogen based on animal inhalation studies as early as 2006. France moved to ban titanium dioxide as a food additive in 2020. The US Food and Drug Administration, as of this writing, continues to list it as generally recognized as safe for food use, citing the distinction between ingested bulk particles and inhaled nanoparticles.

Silver nanoparticles, incorporated into textiles, food storage containers, and wound dressings, have been shown in laboratory settings to exhibit cytotoxicity at concentrations that raise questions about cumulative exposure from daily-use products. Studies published in journals including Environmental Health Perspectives and Nanotoxicology have documented silver nanoparticle accumulation in liver, spleen, and kidney tissue in animal models, along with associated inflammatory markers.

For zinc oxide nanoparticles in sunscreens, the regulatory picture is particularly contested. The FDA issued a proposed rule in 2019 requesting additional data on zinc oxide and titanium dioxide nanoparticle absorption through skin, acknowledging that existing data were insufficient to confirm safety. Studies published since then have detected zinc in blood samples from sunscreen users, though researchers disagree on whether detected concentrations are biologically significant.

The Regulatory Gap

The FDA, the Environmental Protection Agency, and the Consumer Product Safety Commission each have partial jurisdiction over different categories of products containing engineered nanoparticles. None has implemented a comprehensive, nanoparticle-specific regulatory framework that requires manufacturers to characterize particle size distribution, surface chemistry, or potential for biological accumulation before bringing a product to market.

Manufacturers are generally not required to disclose the presence of engineered nanoparticles on product labels, though the European Union has moved toward mandatory labeling for cosmetics and certain food products. In the United States, a nanoparticle-enhanced sunscreen and a conventional mineral sunscreen may carry identical ingredient declarations—both listing "zinc oxide"—with no indication that the particle sizes differ by orders of magnitude.

"The regulatory gap is not a product of bad intentions," said a former FDA science advisor who now consults on nanotechnology policy. "It is a product of institutional bandwidth and the pace of innovation. These materials entered commerce faster than the agencies could develop testing frameworks. And once a material is on the market and generating revenue, the political economy of pulling it back is complicated."

The EPA's Toxic Substances Control Act program does require reporting for certain new nanomaterials, but enforcement has been inconsistent, and the threshold for what constitutes a "new" nanomaterial versus a reformulation of an existing substance has been a persistent source of regulatory ambiguity.

What Researchers Actually Recommend

Among the toxicologists and materials scientists actively working in this space, the prevailing view is neither blanket alarm nor uncritical reassurance. Most researchers interviewed for this article described their position as one of structured caution—advocating for more rigorous testing without calling for categorical bans on products where evidence of harm remains preliminary.

Several specific recommendations recur across expert conversations. First, exposure characterization needs to improve: researchers need better data on how much of which nanoparticles Americans are actually encountering across their full portfolio of daily products, not just from individual items studied in isolation. Second, long-term bioaccumulation studies in humans—not just rodents—are urgently needed for the highest-volume nanoparticles in commerce. Third, surface chemistry and particle coating must be incorporated into safety assessments, since two particles of identical core composition but different surface treatments can exhibit dramatically different biological behavior.

For consumers seeking practical guidance in the interim, experts generally suggest prioritizing products where nanoparticle exposure is incidental rather than direct—preferring spray-format products that risk inhalation over topical applications, for instance, or being attentive to whether food-contact materials carry any available third-party certification.

"We are not in a position to tell people that these products are definitely harming them," said one researcher whose laboratory studies nanoparticle pulmonary toxicity. "We are in a position to say that we do not yet have the data to confirm they are not. In a rational regulatory environment, that uncertainty should carry more weight than it currently does."

The Path Toward Accountability

Closing the knowledge gap will require sustained investment in nanotoxicology research, modernized testing protocols that account for nanoscale-specific properties, and regulatory frameworks that require characterization data before commercial approval rather than after. Several academic consortia and federal programs—including the National Toxicology Program's nanotechnology safety initiative—are working toward those goals, but funding and timelines remain mismatched with the pace at which new nanoparticle-enhanced products reach store shelves.

Until that alignment improves, the invisible ingredients in everyday American consumer products will remain, in a very real scientific sense, inadequately understood—present at the nanoscale, consequential at the biological scale, and largely unexamined at the regulatory scale.